Abstract
Gout is one of the most common rheumatologic arthritic diseases in the United States. Preventing future gout attacks requires lowering serum urate levels to promote dissolution of urate crystals, which is accomplished by reducing the production of serum uric acid or promoting its excretion. Xanthene oxidase inhibitors (XOIs), including allopurinol and febuxostat, are first-line agents for the prevention of acute attacks. Probenecid, a uricosuric agent, is an appropriate adjunctive therapy or second-line agent when XOIs are contraindicated or poorly tolerated. Recently, several third-line agents (e.g., pegloticase, lesinurad) have become available for the treatment of refractory gout.
| Original language | English (US) |
|---|---|
| Pages | 33-37 |
| Number of pages | 5 |
| Volume | 42 |
| No | 3 |
| Specialist publication | U.S. Pharmacist |
| State | Published - Mar 1 2017 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacy
- Pharmacology
- Pharmaceutical Science
Cite this
Urate-lowering therapy for the prevention and treatment of gout flare. / Tilleman, Jennifer A.; Desimone, Edward M.; McAuliffe, Richard.
In: U.S. Pharmacist, Vol. 42, No. 3, 01.03.2017, p. 33-37.Research output: Contribution to specialist publication › Article
}
TY - GEN
T1 - Urate-lowering therapy for the prevention and treatment of gout flare
AU - Tilleman, Jennifer A.
AU - Desimone, Edward M.
AU - McAuliffe, Richard
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Gout is one of the most common rheumatologic arthritic diseases in the United States. Preventing future gout attacks requires lowering serum urate levels to promote dissolution of urate crystals, which is accomplished by reducing the production of serum uric acid or promoting its excretion. Xanthene oxidase inhibitors (XOIs), including allopurinol and febuxostat, are first-line agents for the prevention of acute attacks. Probenecid, a uricosuric agent, is an appropriate adjunctive therapy or second-line agent when XOIs are contraindicated or poorly tolerated. Recently, several third-line agents (e.g., pegloticase, lesinurad) have become available for the treatment of refractory gout.
AB - Gout is one of the most common rheumatologic arthritic diseases in the United States. Preventing future gout attacks requires lowering serum urate levels to promote dissolution of urate crystals, which is accomplished by reducing the production of serum uric acid or promoting its excretion. Xanthene oxidase inhibitors (XOIs), including allopurinol and febuxostat, are first-line agents for the prevention of acute attacks. Probenecid, a uricosuric agent, is an appropriate adjunctive therapy or second-line agent when XOIs are contraindicated or poorly tolerated. Recently, several third-line agents (e.g., pegloticase, lesinurad) have become available for the treatment of refractory gout.
UR - http://www.scopus.com/inward/record.url?scp=85017537116&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017537116&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85017537116
VL - 42
SP - 33
EP - 37
JO - U.S. Pharmacist
JF - U.S. Pharmacist
SN - 0148-4818
ER -